Formycon Strengthens Biosimilars Portfolio With Athos Assets
Deal Will Be Paid For With A Consideration Worth Approximately €650m
Executive Summary
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
You may also be interested in...
Formycon Pipeline Climbs To Six As It Adds Two Biosimilars
Ahead of entering the planned commercialization stage for its first biosimilar product, German biotech Formycon has revealed a series of major announcements, including that it has beefed up its pipeline with an additional two new assets. Meanwhile, it expects to soon find a commercialization partner for its proposed Stelara biosimilar.
Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.